Skip to main content
TCMD
NASDAQ Industrial Applications And Services

Tactile Medical Q3 Revenue Up 7% to $91.9M, FY26 EBITDA Guidance Raised to $50-52M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$22.87
Mkt Cap
$518.058M
52W Low
$14.84
52W High
$37.77
52W Position info
54% above low
Off High info
39% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

TCMD sits 54% above its 52-week low of $14.84.

Summary

Tactile Medical posted Q3 2026 revenue of $91.9M, up 7%, as lymphedema growth of 13% offset a 25% decline in airway clearance. Management raised full-year Adjusted EBITDA guidance to $50-52M while reaffirming revenue of $360-366M.


Key Events · Earnings and Guidance · TCMD

  • Q3 Revenue Grows 7% to $91.9M

    Total revenue rose $6.1M, or 7%, to $91.9M from $85.8M a year earlier. Lymphedema sales and rentals increased 13% to $81.8M, offset by a 25% decline in airway clearance to $10.0M tied to the AffloVest DME inventory transition.

  • FY26 EBITDA Guidance Raised

    Full-year 2026 Adjusted EBITDA guidance moved to $50-52M from the prior $49-51M, while revenue guidance was reaffirmed at $360-366M, or roughly 9-11% growth over 2025's $329.5M.

  • Margins Expand, Net Income Slips

    Gross margin rose to 77% from 76%, the 12th consecutive quarter of expansion, but operating expenses grew 13% to $60.9M and net income fell to $7.2M, or $0.31 per diluted share, from $8.2M, or $0.36.

  • Balance Sheet and Buyback

    The company held $75.1M in cash with no outstanding credit agreement borrowings as of September 30, 2026, and repurchased $6.2M of stock in Q3, leaving $12.5M available under the $25.0M program that expires November 3, 2027.


Analysis · TCMD · Industrial Applications And Services

The headline 7% revenue growth marks a deceleration from the 12% pace of the first nine months and from the 23% reported in Q1, and the top line landed essentially where the company had already guided. What changed is profitability: management lifted the full-year Adjusted EBITDA range to $50-52M from $49-51M while holding revenue at $360-366M, meaning the improvement comes from margin and cost discipline rather than extra volume. Gross margin expanded for a 12th straight quarter to 77%, but operating expenses grew 13% and net income fell to $7.2M from $8.2M, so the earnings line is thinner even as the business scales. The lymphedema franchise is doing the work — up 13% to $81.8M — while airway clearance fell 25% on the AffloVest distribution transition, a drag that should ease as the next-generation system ramps. With $75.1M of cash, no borrowings, and $12.5M left on the buyback, the balance sheet gives management room to keep investing through the transition.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TCMD was trading at $22.87 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $518.1M. The 52-week trading range was $14.84 to $37.77. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TCMD - Latest Insights

TCMD
Nov 02, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $22.87
Real-time Price: $26.05 info
Change: +$3.18 (+14%) info
Market Cap: $583.556M info
TCMD
Nov 02, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $22.87
Real-time Price: $26.05 info
Change: +$3.18 (+14%) info
Market Cap: $583.556M info
TCMD
Aug 10, 2026, 4:21 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $29.72
Real-time Price: $26.05 info
Change: -$3.67 (-12%) info
Market Cap: $583.556M info
TCMD
Jul 13, 2026, 9:23 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $29.83
Real-time Price: $26.05 info
Change: -$3.78 (-13%) info
Market Cap: $583.556M info
TCMD
Jul 13, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $29.83
Real-time Price: $26.05 info
Change: -$3.78 (-13%) info
Market Cap: $583.556M info